Ideaya Biosciences saw the highest growth of 6.99% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.16% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Ideaya Biosciences’s patent filings and grants. Buy the databook here.
Ideaya Biosciences has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with six publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 40% of filings. The World Intellectual Property Organization(WIPO), United States(US), European Patent Office(EPO), and Colombia(CO) patent Office are among the top ten patent offices where Ideaya Biosciences is filings its patents. Among the top granted patent authorities, Ideaya Biosciences has 100% of its grants in Spain(ES).
Roche could be the strongest competitor for Ideaya Biosciences
Patents related to rare diseases lead Ideaya Biosciences's portfolio
Ideaya Biosciences has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Solid tumor related patents lead Ideaya Biosciences portfolio followed by melanoma, and breast cancer
Ideaya Biosciences has highest number of patents in solid tumor followed by melanoma, breast cancer, leukemia, and bladder carcinoma.
For comprehensive analysis of Ideaya Biosciences's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.